PT2279008T - Composições farmacêuticas de paclitaxel, análogos de paclitaxel ou conjugados de paclitaxel e métodos relacionados de preparação e utilização - Google Patents

Composições farmacêuticas de paclitaxel, análogos de paclitaxel ou conjugados de paclitaxel e métodos relacionados de preparação e utilização

Info

Publication number
PT2279008T
PT2279008T PT09733078T PT09733078T PT2279008T PT 2279008 T PT2279008 T PT 2279008T PT 09733078 T PT09733078 T PT 09733078T PT 09733078 T PT09733078 T PT 09733078T PT 2279008 T PT2279008 T PT 2279008T
Authority
PT
Portugal
Prior art keywords
paclitaxel
preparation
pharmaceutical compositions
conjugates
related methods
Prior art date
Application number
PT09733078T
Other languages
English (en)
Portuguese (pt)
Inventor
Demeule Michel
Regina Anthony
Che Christian
Beliveau Richard
Gagnon Catherine
Castaigne Jean-Paul
Gabathuler Reinhard
Original Assignee
Angiochem Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Angiochem Inc filed Critical Angiochem Inc
Publication of PT2279008T publication Critical patent/PT2279008T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT09733078T 2008-04-18 2009-04-20 Composições farmacêuticas de paclitaxel, análogos de paclitaxel ou conjugados de paclitaxel e métodos relacionados de preparação e utilização PT2279008T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US12467708P 2008-04-18 2008-04-18

Publications (1)

Publication Number Publication Date
PT2279008T true PT2279008T (pt) 2019-05-20

Family

ID=41198750

Family Applications (1)

Application Number Title Priority Date Filing Date
PT09733078T PT2279008T (pt) 2008-04-18 2009-04-20 Composições farmacêuticas de paclitaxel, análogos de paclitaxel ou conjugados de paclitaxel e métodos relacionados de preparação e utilização

Country Status (16)

Country Link
US (1) US8710013B2 (enExample)
EP (1) EP2279008B1 (enExample)
JP (2) JP5860698B2 (enExample)
CN (1) CN102026667B (enExample)
AU (1) AU2009238187B2 (enExample)
BR (1) BRPI0910557A2 (enExample)
CA (1) CA2721019C (enExample)
DK (1) DK2279008T3 (enExample)
ES (1) ES2721148T3 (enExample)
MX (1) MX355683B (enExample)
PL (1) PL2279008T3 (enExample)
PT (1) PT2279008T (enExample)
RU (1) RU2518240C2 (enExample)
TR (1) TR201905480T4 (enExample)
WO (1) WO2009127072A1 (enExample)
ZA (1) ZA201007170B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4903036B2 (ja) 2003-01-06 2012-03-21 アンジオケム・インコーポレーテッド 血液脳関門を通過する担体としてのアプロチニンおよび類似体
BRPI0520032A2 (pt) 2005-02-18 2009-04-14 Angiochem Inc moléculas para transportar um composto através da barreira hematoencefálica
US20090016959A1 (en) * 2005-02-18 2009-01-15 Richard Beliveau Delivery of antibodies to the central nervous system
WO2007009229A1 (en) 2005-07-15 2007-01-25 Angiochem Inc. Use of aprotinin polypeptides as carriers in pharmaceutical conjugates
EP2074142A4 (en) 2006-10-19 2010-10-27 Angiochem Inc COMPOUNDS FOR STIMULATING THE FUNCTION OF P-GLYCOPROTEIN AND APPLICATIONS THEREOF
US9365634B2 (en) 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
WO2010043047A1 (en) 2008-10-15 2010-04-22 Angiochem Inc. Conjugates of glp-1 agonists and uses thereof
US9914754B2 (en) 2008-12-05 2018-03-13 Angiochem Inc. Conjugates of neurotensin or neurotensin analogs and uses thereof
AU2009327267A1 (en) 2008-12-17 2011-07-14 Angiochem, Inc. Membrane type-1 matrix metalloprotein inhibitors and uses thereof
ES2729261T3 (es) 2009-04-20 2019-10-31 Angiochem Inc Tratamiento del cáncer de ovario utilizando un agente anticancerígeno conjugado con un análogo de Angiopep-2
WO2011000095A1 (en) 2009-07-02 2011-01-06 Angiochem Inc. Multimeric peptide conjugates and uses thereof
SG10201503234SA (en) 2010-05-03 2015-06-29 Teikoku Pharma Usa Inc Non-Aqueous Taxane Pro-Emulsion Formulations and Methods of Making and Using the Same
US8842114B1 (en) 2011-04-29 2014-09-23 Nvidia Corporation System, method, and computer program product for adjusting a depth of displayed objects within a region of a display
WO2013043864A1 (en) * 2011-09-23 2013-03-28 The Board Of Regents Of The University Of Texas System Compositions and methods related to endothelial targeting
JP2015526434A (ja) 2012-08-14 2015-09-10 アンジオケム インコーポレーテッド ペプチド−デンドリマーコンジュゲート及びその使用
JO3685B1 (ar) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
CN105585614B (zh) * 2014-10-24 2019-06-07 中国科学技术大学 用于淀粉样蛋白显像的血管肽及其衍生物
EP3270912B1 (en) * 2015-03-16 2021-08-18 Meridian Lab Pharmaceutical compositions containing taxane-cyclodextrin complexes, method of making and methods of use
EP3307326B9 (en) * 2015-06-15 2021-02-24 Angiochem Inc. Methods for the treatment of leptomeningeal carcinomatosis
EP3453390B1 (en) * 2016-05-06 2024-02-14 Biodynamic Research Foundation Polymerized drug-containing pharmaceutical composition
JP7421499B2 (ja) * 2018-05-15 2024-01-24 アメリカ合衆国 腫瘍転移および腫瘍発生の予防および治療のための製剤および方法
EP3866783A4 (en) * 2018-10-16 2022-08-03 US Nano Food & Drug Inc INTRATUMOR INJECTION FORMULATION
CN110227086A (zh) * 2019-07-13 2019-09-13 高天荣 一种用人工种植红豆杉制备口服广普抗癌药的方法
US11752165B2 (en) 2020-04-13 2023-09-12 US Nano Food & Drug, Inc Basic chemotherapeutic intratumour injection formulation
CN111671759A (zh) * 2020-07-15 2020-09-18 五邑大学 一种协同抗胰腺癌干细胞的药物组合
CN113406015B (zh) * 2021-05-31 2023-01-13 内蒙古师范大学 一种近岸和内陆水域水体的透明度计算方法和系统
TW202440073A (zh) * 2023-02-22 2024-10-16 美商N1生命股份有限公司 汰癌勝結合物化合物及包含該化合物的醫藥組成物

Family Cites Families (142)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4671958A (en) * 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US5910304A (en) 1982-12-13 1999-06-08 Texas A&M University System Low-dose oral administration of interferons
US4801575A (en) * 1986-07-30 1989-01-31 The Regents Of The University Of California Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4902505A (en) * 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
CA1320905C (en) 1986-11-06 1993-08-03 Joseph M. Cummins Treatment of immuno-resistant disease
US4904768A (en) * 1987-08-04 1990-02-27 Bristol-Myers Company Epipodophyllotoxin glucoside 4'-phosphate derivatives
GB2208511A (en) 1987-08-07 1989-04-05 Bayer Ag Variants of bovine pancreatic trypsin inhibitor produced by recombinant dna technology
US4942184A (en) * 1988-03-07 1990-07-17 The United States Of America As Represented By The Department Of Health And Human Services Water soluble, antineoplastic derivatives of taxol
US5632990A (en) * 1988-04-22 1997-05-27 Cancer Research Campaign Tech. Ltd. Treatment for tumors comprising conjugated antibody A5B7 and a prodrug
US5258499A (en) * 1988-05-16 1993-11-02 Vestar, Inc. Liposome targeting using receptor specific ligands
US5028697A (en) * 1988-08-08 1991-07-02 Eli Lilly And Company Cytotoxic antibody conjugates of hydrazide derivatized methotrexate analogs via simple organic linkers
US5169933A (en) * 1988-08-15 1992-12-08 Neorx Corporation Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5948634A (en) * 1988-12-21 1999-09-07 The General Hospital Coporation Neural thread protein gene expression and detection of alzheimer's disease
DE3912638A1 (de) 1989-04-18 1990-10-31 Bayer Ag Gentechnologisch hergestellte homologe des alzheimer protease inhibitors, wirtstaemme sowie expressionsvektoren fuer ihre herstellung und ihre verwendung als arzneimittel
US5126249A (en) 1989-05-09 1992-06-30 Eli Lilly And Company Enzymatic removal of a protein amino-terminal sequence
US6020145A (en) * 1989-06-30 2000-02-01 Bristol-Myers Squibb Company Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96
US6475781B1 (en) * 1990-05-17 2002-11-05 Dana-Farber Cancer Institute, Inc. Trans-dominant suppressor genes for oligomeric proteins
GB9017008D0 (en) 1990-08-02 1990-09-19 Erba Carlo Spa Process for the enzymatic preparation of basic fibroblast growth factor
US5714167A (en) * 1992-06-15 1998-02-03 Emisphere Technologies, Inc. Active agent transport systems
US6495513B1 (en) * 1991-03-11 2002-12-17 Curis, Inc. Morphogen-enhanced survival and repair of neural cells
US5955444A (en) * 1991-08-09 1999-09-21 Massachusetts Institute Of Technology Method of inhibiting abnormal tau hyper phosphorylation in a cell
US5627270A (en) * 1991-12-13 1997-05-06 Trustees Of Princeton University Glycosylated steroid derivatives for transport across biological membranes and process for making and using same
US5204354A (en) 1992-02-14 1993-04-20 Merck & Co., Inc. Substituted quinazolinones as neurotensin antagonists useful in the treatment of CNS disorders
GB9213077D0 (en) 1992-06-19 1992-08-05 Erba Carlo Spa Polymerbound taxol derivatives
CA2145517A1 (en) * 1992-09-25 1994-04-14 Ignace Lasters Bovine pancreatic trypsin inhibitor derived inhibitors of factor viia - tissue factor complex
EP0599303A3 (en) * 1992-11-27 1998-07-29 Takeda Chemical Industries, Ltd. Peptide conjugate
WO1994019692A1 (en) * 1993-02-18 1994-09-01 The General Hospital Corporation Alzheimer's disease therapeutics
ZA963619B (en) * 1995-05-08 1996-11-22 Scios Inc Protease inhibitor peptides
US5780265A (en) 1995-06-05 1998-07-14 Genentech, Inc. Kunitz type plasma kallikrein inhibitors
DK0891426T3 (da) * 1996-03-11 2006-10-02 Bayer Corp Humant bikunin
DE19636889A1 (de) 1996-09-11 1998-03-12 Felix Dr Kratz Antineoplastisch wirkende Transferrin- und Albuminkonjugate zytostatischer Verbindungen aus der Gruppe der Anthrazykline, Alkylantien, Antimetabolite und Cisplatin-Analoga und diese enthaltende Arzneimittel
EP0932390A1 (en) * 1996-10-11 1999-08-04 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method
US6056973A (en) * 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
US5948750A (en) 1996-10-30 1999-09-07 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
AU6682598A (en) 1997-03-04 1998-09-22 Bio-Technology General Corporation Isolation of tissue specific peptide ligands and their use for targeting pharmaceuticals to organs
US6126965A (en) * 1997-03-21 2000-10-03 Georgetown University School Of Medicine Liposomes containing oligonucleotides
GB9705903D0 (en) 1997-03-21 1997-05-07 Elliott Gillian D VP22 Proteins and uses thereof
AU734827B2 (en) * 1997-05-21 2001-06-21 Board Of Trustees Of The Leland Stanford Junior University Composition and method for enhancing transport across biological membranes
US6391305B1 (en) 1997-09-10 2002-05-21 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
US6093692A (en) * 1997-09-25 2000-07-25 The University Of Southern California Method and compositions for lipidization of hydrophilic molecules
US6475481B2 (en) * 1997-11-18 2002-11-05 Canji Inc Purging of stem cell products
WO1999026657A1 (en) * 1997-11-25 1999-06-03 Musc Foundation For Research Development Inhibitors of nitric oxide synthase
US6036949A (en) 1998-03-05 2000-03-14 Amarillo Biosciences, Inc. Treatment of fibromyalgia with low doses of interferon
US5981564A (en) * 1998-07-01 1999-11-09 Universite Laval Water-soluble derivatives of paclitaxel, method for producing same and uses thereof
US6703381B1 (en) * 1998-08-14 2004-03-09 Nobex Corporation Methods for delivery therapeutic compounds across the blood-brain barrier
US5922754A (en) * 1998-10-02 1999-07-13 Abbott Laboratories Pharmaceutical compositions containing paclitaxel
MXPA01008699A (es) * 1999-02-24 2002-06-21 Uab Research Foundation Derivados de taxano para terapia de cancer dirigida. .
US6180607B1 (en) * 1999-08-05 2001-01-30 Christopher Davies Protein having proteinase inhibitor activity
US6713454B1 (en) * 1999-09-13 2004-03-30 Nobex Corporation Prodrugs of etoposide and etoposide analogs
PT1214292E (pt) 1999-09-24 2007-09-14 Genentech Inc Derivados de tirosina
US6136846A (en) * 1999-10-25 2000-10-24 Supergen, Inc. Formulation for paclitaxel
DE19953696A1 (de) 1999-11-09 2001-05-10 Alexander Cherkasky Selektive proteolytische Synzyme (SPS)
US6919370B2 (en) * 2000-11-28 2005-07-19 Transform Pharmaceuticals, Inc. Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof
US6825166B2 (en) * 2001-03-23 2004-11-30 Tapestry Pharmaceuticals, Inc. Molecular conjugates for use in treatment of cancer
US20030170891A1 (en) * 2001-06-06 2003-09-11 Mcswiggen James A. RNA interference mediated inhibition of epidermal growth factor receptor gene expression using short interfering nucleic acid (siNA)
JP4202250B2 (ja) * 2001-07-25 2008-12-24 バイオマリン ファーマシューティカル インコーポレイテッド 血液脳関門輸送を調節するための組成物および方法
US20040161776A1 (en) 2001-10-23 2004-08-19 Maddon Paul J. PSMA formulations and uses thereof
US7192921B2 (en) * 2001-11-08 2007-03-20 The Burnham Institute Peptides that home to tumor lymphatic vasculature and methods of using same
EP1472351B1 (en) * 2002-02-07 2007-06-20 Yissum Research Development Company Of The Hebrew University Of Jerusalem Amino acid sequences capable of facilitating penetration across a biological barrier
WO2003097671A1 (en) 2002-03-29 2003-11-27 Creagene Inc. Cytoplasmic transduction peptides and uses thereof
US6881829B2 (en) 2002-04-26 2005-04-19 Chimeracom, L.L.C. Chimeric hybrid analgesics
JP2005537244A (ja) * 2002-06-28 2005-12-08 ナステック・ファーマシューティカル・カンパニー・インコーポレーテッド 療法化合物の粘膜搬送を増進させるための、上皮接合部接着分子の生理機能を調節する組成物および方法
DK2284266T3 (da) * 2002-11-14 2014-01-13 Thermo Fisher Scient Biosciences Inc sIRNA-MOLEKYLE MOD TP53
US7829694B2 (en) * 2002-11-26 2010-11-09 Medtronic, Inc. Treatment of neurodegenerative disease through intracranial delivery of siRNA
US7388079B2 (en) 2002-11-27 2008-06-17 The Regents Of The University Of California Delivery of pharmaceutical agents via the human insulin receptor
US20040102369A1 (en) 2002-11-27 2004-05-27 The Regents Of The University Of California Transport of basic fibroblast growth factor across the blood brain barrier
US7319090B2 (en) 2002-11-27 2008-01-15 University Of North Carolina At Chapel Hill Methods of treating cerebral ischemia
JP4903036B2 (ja) 2003-01-06 2012-03-21 アンジオケム・インコーポレーテッド 血液脳関門を通過する担体としてのアプロチニンおよび類似体
US20040162284A1 (en) 2003-02-19 2004-08-19 Harris Herbert W. Method of lowering body temperature with (S) tofisopam
WO2005046569A2 (en) 2003-04-08 2005-05-26 Biotempt B.V. Pharmaceutical compositions for the treatment of sars
BRPI0409133B8 (pt) * 2003-04-08 2021-05-25 Progenics Pharm Inc preparações farmacêuticas estavéis compreendendo metilnaltrexona
ES2702942T3 (es) * 2003-04-17 2019-03-06 Alnylam Pharmaceuticals Inc Agentes de ARNi modificados
EP2281577B1 (en) * 2003-05-14 2016-11-16 ImmunoGen, Inc. Drug conjugate composition
WO2004108071A2 (en) * 2003-06-05 2004-12-16 Salk Institute For Biological Studies Targeting polypeptides to the central nervous system
CA2525236C (en) 2003-06-20 2015-03-24 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
US20050026823A1 (en) 2003-06-20 2005-02-03 Biomarin Pharmaceutical Inc. Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
AU2004263458B2 (en) 2003-08-08 2010-06-24 Actgen, Inc. Polypeptides having brain-localizing activity and uses thereof
JP2007512001A (ja) 2003-08-28 2007-05-17 バイオレクシス ファーマシューティカル コーポレイション Epoミメティックペプチドおよび融合タンパク質
EP1510206A1 (en) * 2003-08-29 2005-03-02 Novagali Pharma SA Self-nanoemulsifying oily formulation for the administration of poorly water-soluble drugs
US20050058702A1 (en) * 2003-09-17 2005-03-17 Ben-Sasson Shmuel A. Compositions capable of facilitating penetration across a biological barrier
US20050208095A1 (en) * 2003-11-20 2005-09-22 Angiotech International Ag Polymer compositions and methods for their use
US7208174B2 (en) * 2003-12-18 2007-04-24 Hoffmann-La Roche Inc. Liposome compositions
MX2007000728A (es) 2004-07-21 2007-03-15 Ambrx Inc Polipeptidos biosinteticos que utilizan amino acidos no naturalmente codificados.
US20090221477A1 (en) * 2004-07-26 2009-09-03 Asterion Limited Linkers
EP1799826B1 (en) * 2004-09-29 2009-08-12 Children's Memorial Hospital siRNA-MEDIATED GENE SILENCING OF ALPHA SYNUCLEIN
US9002652B1 (en) 2005-01-27 2015-04-07 Institute For Systems Biology Methods for identifying and using organ-specific proteins in blood
BRPI0520032A2 (pt) * 2005-02-18 2009-04-14 Angiochem Inc moléculas para transportar um composto através da barreira hematoencefálica
US20090016959A1 (en) * 2005-02-18 2009-01-15 Richard Beliveau Delivery of antibodies to the central nervous system
SG166775A1 (en) * 2005-02-18 2010-12-29 Abraxis Bioscience Llc Combinations and modes of administration of therapeutic agents and combination therapy
WO2006108052A2 (en) 2005-04-06 2006-10-12 Genzyme Corporation Peg and polysialic lysosomal enzyme conjugates via acid labile linkers for therapeutic targeting
WO2006124737A2 (en) * 2005-05-12 2006-11-23 Tapestry Pharmaceuticals, Inc. Molecular constructs suitable for targeted conjugates
US8877714B2 (en) 2005-06-14 2014-11-04 Raptor Pharmaceutical Inc. Compositions comprising receptor-associated protein (RAP) variants specific for LRP2 and uses thereof
WO2007009229A1 (en) 2005-07-15 2007-01-25 Angiochem Inc. Use of aprotinin polypeptides as carriers in pharmaceutical conjugates
JP2009502135A (ja) 2005-07-19 2009-01-29 ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイ 血液脳関門を越えるための、および脳癌細胞内への輸送因子、並びにその使用方法
GB0517092D0 (en) * 2005-08-19 2005-09-28 Novartis Ag New compositions containing taxane derivatives
HUE042678T2 (hu) * 2005-08-31 2019-07-29 Abraxis Bioscience Llc Vízben rosszul oldódó gyógyszerhatóanyagok és antimikrobiális szerek
US9062126B2 (en) 2005-09-16 2015-06-23 Raptor Pharmaceuticals Inc. Compositions comprising receptor-associated protein (RAP) variants specific for CR-containing proteins and uses thereof
US8142781B2 (en) 2005-10-07 2012-03-27 Armagen Technologies, Inc. Fusion proteins for blood-brain barrier delivery
CA2627585A1 (en) * 2005-11-01 2007-05-10 Alnylam Pharmaceuticals, Inc. Rnai inhibition of influenza virus replication
WO2007053946A1 (en) 2005-11-09 2007-05-18 Conjuchem Biotechnologies Inc. Method of treating diabetes and/or obesity with reduced nausea side effects using an insulinotropic peptide conjugated to albumin
AR054215A1 (es) * 2006-01-20 2007-06-13 Eriochem Sa Una formulacion farmaceutica de un taxano, una composicion solida de un taxano liofilizado a partir de una solucion de acido acetico, un procedimiento para la preparacion de dicha composicion solida de un taxano, una composicion solubilizante de un taxano liofilizado, y un conjunto de elementos (kit
CA2657649A1 (en) 2006-07-13 2008-08-21 Burnham Institute For Medical Research Methods and compositions for targeting gc1qr/p32
CN101594878A (zh) 2006-09-18 2009-12-02 雷普特药品公司 通过给予受体相关蛋白(rap)-缀合物对肝病症的治疗
EP2074142A4 (en) * 2006-10-19 2010-10-27 Angiochem Inc COMPOUNDS FOR STIMULATING THE FUNCTION OF P-GLYCOPROTEIN AND APPLICATIONS THEREOF
US9399675B2 (en) 2007-02-28 2016-07-26 The Board Of Regents Of The University Of Oklahoma Methods and compositions for diagnosing Alzheimer's disease and age-related macular degeneration
KR20100015786A (ko) 2007-03-21 2010-02-12 랩터 파마슈티컬 인코포레이티드 환형의 수용체-연관된 단백질(rap) 펩티드
AU2008255556B2 (en) 2007-05-29 2014-08-07 Angiochem, Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
US8802631B2 (en) * 2007-09-17 2014-08-12 Ludwig Institute For Cancer Research Ltd. Peptides and methods for the treatment of gliomas and other cancers
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
US9914754B2 (en) * 2008-12-05 2018-03-13 Angiochem Inc. Conjugates of neurotensin or neurotensin analogs and uses thereof
US20110059187A1 (en) 2009-06-03 2011-03-10 Dicerna Pharmaceuticals, Inc. Peptide dicer substrate agents and methods for their specific inhibition of gene expression
ES2562463T3 (es) 2009-07-14 2016-03-04 Mayo Foundation For Medical Education And Research Administración no covalente, mediada por péptidos, de agentes activos a través de la barrera hematoencefálica
US9095541B2 (en) 2009-11-24 2015-08-04 Arch Cancer Therapeutics, Inc. Brain tumor targeting peptides and methods
US8530429B2 (en) 2009-11-24 2013-09-10 Arch Cancer Therapeutics, Inc. Brain tumor targeting peptides and methods
EP2333074A1 (en) 2009-12-14 2011-06-15 Robert Steinfeld Substances and methods for the treatment of lysosmal storage diseases
EP3338770B1 (en) 2010-03-08 2023-06-07 Sloan-Kettering Institute For Cancer Research Cdc7 kinase inhibitors and uses thereof
US9102697B2 (en) 2010-03-22 2015-08-11 President And Fellows Of Harvard College Trioxacarcins and uses thereof
WO2011119608A1 (en) 2010-03-26 2011-09-29 University Of Tennessee Research Foundation Peptides that specifically target amyloid deposits
EP2558503B1 (en) 2010-04-14 2015-12-09 National Research Council of Canada Compositions and methods for brain delivery of analgesic peptides
US8218280B2 (en) 2010-07-08 2012-07-10 Schneider Electric USA, Inc. Secondary thermal sensor for primary conductors
JP2013540694A (ja) 2010-08-06 2013-11-07 ウー3・フアルマ・ゲー・エム・ベー・ハー Her3結合剤の前立腺治療における使用
CN102406949B (zh) 2010-09-21 2013-05-29 复旦大学 一种靶向示踪的多模式诊断纳米影像药物
CN103298474B (zh) 2010-11-10 2016-06-29 无限药品股份有限公司 杂环化合物及其用途
CA2817250A1 (en) 2010-11-18 2012-05-24 The General Hospital Corporation Novel compositions and uses of anti-hypertension agents for cancer therapy
CN102552928A (zh) 2010-12-19 2012-07-11 复旦大学 一种治疗脑部肿瘤的双级靶向递药系统及其制备方法
TWI546305B (zh) 2011-01-10 2016-08-21 英菲尼提製藥股份有限公司 製備異喹啉酮之方法及異喹啉酮之固體形式
CN102614105A (zh) 2011-01-28 2012-08-01 复旦大学 一种脑靶向载两性霉素b聚合物胶束给药系统
WO2012118376A1 (en) 2011-03-01 2012-09-07 To-Bbb Holding B.V. Advanced active liposomal loading of poorly water-soluble substances
US9238716B2 (en) 2011-03-28 2016-01-19 Massachusetts Institute Of Technology Conjugated lipomers and uses thereof
EP2952210A3 (en) 2011-04-07 2016-03-16 Emory University Compositions comprising saccharide binding moieties and methods for targeted therapy
WO2013004716A1 (en) 2011-07-04 2013-01-10 Universität Basel Peptide beads
AU2012284088B2 (en) 2011-07-19 2015-10-08 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
WO2013012918A1 (en) 2011-07-19 2013-01-24 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
CA2846431A1 (en) 2011-08-29 2013-03-07 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
US9630979B2 (en) 2011-09-29 2017-04-25 Infinity Pharmaceuticals, Inc. Inhibitors of monoacylglycerol lipase and methods of their use
PE20181541A1 (es) 2011-10-27 2018-09-26 Massachusetts Inst Technology Derivados de aminoacidos funcionalizados en la terminal n capaces de formar microesferas encapsuladoras de farmaco
WO2013071272A1 (en) 2011-11-11 2013-05-16 Intellikine, Llc Kinase inhibitor polymorphs
MX2014006594A (es) 2011-12-01 2015-09-16 Angiochem Inc Compuestos de enzimas lisosomales apuntados.
SI2790668T1 (sl) 2011-12-13 2021-01-29 Engeneic Molecular Delivery Pty Ltd. Iz bakterij izhajajoče intaktne minicelice za dostavo terapevtskih sredstev v možganske tumorje
WO2013120107A1 (en) 2012-02-09 2013-08-15 University Of Rochester Methods and compositions for treating a subject to inhibit hearing loss
EP2819686A4 (en) 2012-03-02 2016-05-25 Icahn School Med Mount Sinai PROTHYMOSIN ALPHA VARIANTS AND METHODS OF USE

Also Published As

Publication number Publication date
EP2279008A1 (en) 2011-02-02
CN102026667A (zh) 2011-04-20
CA2721019A1 (en) 2009-10-22
ES2721148T3 (es) 2019-07-29
RU2518240C2 (ru) 2014-06-10
EP2279008A4 (en) 2013-09-04
PL2279008T3 (pl) 2020-03-31
EP2279008B1 (en) 2019-03-06
TR201905480T4 (tr) 2019-05-21
US8710013B2 (en) 2014-04-29
AU2009238187A1 (en) 2009-10-22
BRPI0910557A2 (pt) 2015-09-29
JP2011516587A (ja) 2011-05-26
WO2009127072A8 (en) 2009-12-30
HK1154795A1 (en) 2012-05-04
DK2279008T3 (en) 2019-04-29
JP2015157825A (ja) 2015-09-03
WO2009127072A1 (en) 2009-10-22
US20110112036A1 (en) 2011-05-12
RU2010146718A (ru) 2012-05-27
JP5860698B2 (ja) 2016-02-16
MX2010011339A (es) 2010-12-21
CA2721019C (en) 2015-09-15
ZA201007170B (en) 2012-01-25
MX355683B (es) 2018-04-26
CN102026667B (zh) 2014-06-25
AU2009238187B2 (en) 2014-03-06

Similar Documents

Publication Publication Date Title
ZA201007170B (en) Pharmaceutical compositions of paclitaxel, paclitaxel analogs or paclitaxel conjugates and related methods of preparation and use
IL214822A0 (en) Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof
IL214175A (en) Derivatives of aminotetralin, their pharmaceutical compositions and their use
ZA200900347B (en) Preparation of pharmaceutical compositions
IL195237A0 (en) Conjugates of aziridinyl-epothilone analogs and pharmaceutical compositions comprising same
IL201101A0 (en) Methods of administering tetrahydrobiopterin associated compositions, and methods of measuring
EP2447253A4 (en) DIHYDROPYRIMIDIN COMPOUNDS AND MANUFACTURING METHOD, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
IL206594A (en) The history of azinone-tetrahydropyridoindole and its containing pharmaceutical preparations
IL215497A0 (en) Oxadiazile derivatives and pharmaceutical compositions containing them
IL212219A0 (en) Compositions comprising pyrone analogs and uses thereof
IL213452A0 (en) Phenylpyrimidone compounds, pharmaceutical compositions, preparation methods and uses thereof
GB2454567B (en) Anti-malarial pharmaceutical composition
EP2261221A4 (en) EPOTHILONE ANALOGUES, THEIR PHARMACEUTICAL COMPOSITIONS, THEIR USE AND PREPARATIONS
IL210377A (en) History of Naphthyridone, their preparation and their pharmaceutical preparations
PL2504331T3 (pl) Związek, jego nowe formy, zawierające je kompozycje farmaceutyczne i sposoby otrzymywania oraz zastosowanie
IL213177A0 (en) Crystal forms, methods of preparation, pharmaceutical compositions and uses of nicousamide
EP2296687A4 (en) PHARMACEUTICAL COMPOSITIONS OF SOMATOSTATIN DOPAMINE CONJUGATES
PL2298090T3 (pl) Kompozycja farmaceutyczna lub nutraceutyczna
EP2358693A4 (en) PREPARATION OF DOCETAXEL
ZA201005316B (en) 2-amino-2-phenyl-alkanol derivatives, their preparation and pharmaceutical compositions containing them
ZA201003335B (en) Cephalomannine derivatives and their preparation,medicinal composition and use
ZA201200165B (en) 2-amino-2phenyl-alkanol derivatives, preparation thereof, and pharmaceutical compositions containing same
IL189408A0 (en) Siva3, its preparation and pharmaceutical compositions containing it
GB0724523D0 (en) Pharmaceutical compositions comprising clotrimazole or analogs thereof and their use
HK1152259A (en) Pharmaceutical compositions of somatostatin-dopamine conjugates